2015 Annual Meeting of the European Association for the Study of the Liver*
  • Program Overview
    2015 Annual Meeting of the European Association for the Study of the Liver*
    April 22-26, 2015 | Vienna, Austria
    CCO’s Independent Conference Coverage of EASL 2015 includes Capsule Summaries, expert faculty analysis of key studies, and downloadable slides.
  • Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
    Date Posted: 9/10/2015
  • Featured content
    With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?
    Date Posted: 7/28/2015
  • Featured content
    This downloadable slideset summarizes key studies selected by Andrew J. Muir, MD, David R. Nelson, MD, and Norah Terrault, MD, MPH, regarding the use of investigational agents for treating hepatitis C presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Date Posted: 5/12/2015
  • Featured content
    In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Date Posted: 5/11/2015
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 30 Shown
10 of 30 Shown
Show 10 More
Loading...